API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/servier-receives-regulatory-filing-acceptances-from-fda-and-ema-for-vorasidenib-in-the-treatment-of-idh-mutant-diffuse-glioma-302068104.html
https://www.prnewswire.com/news-releases/fda-and-ema-accept-vorasidenib-regulatory-submissions-for-the-treatment-of-idh-mutant-diffuse-glioma-302064504.html
https://www.prnewswire.com/news-releases/new-analyses-from-pivotal-phase-3-indigo-study-reinforce-vorasidenibs-potential-to-change-the-treatment-paradigm-for-idh-mutant-diffuse-glioma-301992384.html
https://www.prnewswire.com/news-releases/new-vorasidenib-data-at-sno-2023-bolster-serviers-neuro-oncology-clinical-development-program-301984019.html
https://www.prnewswire.com/news-releases/servier-presents-transformational-data-from-pivotal-phase-3-indigo-trial-of-vorasidenib-in-recurrent-or-residual-grade-2-idh-mutant-diffuse-glioma-301841862.html
https://www.fiercebiotech.com/biotech/servier-serves-phase-3-brain-tumor-win-interim-analysis-validating-18b-buyout-agios-unit
https://www.prnewswire.com/news-releases/serviers-pivotal-phase-3-indigo-trial-investigating-vorasidenib-in-idh-mutant-low-grade-glioma-meets-primary-endpoint-of-progression-free-survival-pfs-and-key-secondary-endpoint-of-time-to-next-intervention-ttni-301771421.html
https://investor.agios.com/news-releases/news-release-details/agios-presents-updated-data-phase-1-dose-escalation-study